The Study
Disulfide tethering reveals cryptic pockets in oncogenic KRAS
This study is like poking a LEGO model of a robot with lots of tiny sticky pieces to see where they stick. It shows which spots on the robot might hold a piece, but it doesn’t mean the piece can actually fix the robot or make it move. We don’t know if any of these sticky pieces would work in a real body.
Analysis score
Maximum 0 for a computational/algorithm study.
Where the score came from
Scientists used tiny molecular hooks to probe a cancer-causing protein called KRAS and found secret hiding places where drugs could latch on.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — these hidden spots are new targets for drugs that could treat cancers caused by KRAS mutations, which currently have few treatment options beyond one specific mutation (G12C).
- 2They tested 2,160 tiny molecules on 83 modified versions of the KRAS protein and found some molecules stuck strongly to 5 new hidden spots, with up to 94% of the protein binding to the best molecules.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Communications Chemistry
Year
2026
Authors
T. E. Balius, M. Dyba, V. Kumari, John-Paul Denson, Ming Yi, Alok K. Sharma, Priyanka Prakash, Emily O. Alberico, S. Messing, Vanessa E. Wall, Albert H. Chan, D. Simanshu, D. Nissley, F. McCormick, Dom Esposito, A. Maciag, David M. Turner
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.